Letrozole (API – CAS 112809-51-5)

Letrozole · CAS 112809-51-5 · Oncology / Aromatase Inhibitor

Overview

Letrozole is a widely used active pharmaceutical ingredient (API) in the Oncology / Aromatase Inhibitor therapeutic category. It is supplied as a bulk pharmaceutical-grade material manufactured to meet stringent international quality standards.

Therapeutic Application

Letrozole is a non-steroidal aromatase inhibitor used in the adjuvant and extended adjuvant treatment of postmenopausal women with hormone-receptor-positive early breast cancer.

Specifications

• CAS Number: 112809-51-5
• Appearance: White to off-white crystalline powder
• Typical Assay/Purity: ≥ 99.0%
• Common Pharmacopeial Grades: USP, EP, BP, IP
• Storage: Store in a cool, dry place, away from light
• Shelf Life: Typically 24 months under recommended storage conditions

Regulatory & Compliance

Intravarsity adheres to WHO-GMP manufacturing practices, ensuring that Letrozole is produced in compliance with international quality standards. Availability of regulatory documents such as USDMF, CEP, and EU-GMP certificates, along with Certificates of Analysis (COA) and Certificates of Suitability (COS), is subject to inquiry.

Packaging & Shipping

Letrozole is packaged in 25kg HDPE drums with double LDPE liners, palletized for secure transport. All necessary export documentation is provided, facilitating shipping to key markets including USA, EU, Canada, Australia.

Common Use Cases & Finished Dosage Forms

This API is typically incorporated into various dosage forms including:

• Tablets
• Capsules
• Injectable solutions

Ordering Information

The minimum order quantity (MOQ) for Letrozole is subject to inquiry. Interested parties are encouraged to request a Certificate of Analysis (COA) and a quote via this listing. For further inquiries, please contact Intravarsity directly.